Theragnostic Imaging
Group leader
Molecular imaging modalities are used for in vivo assessment of pathology, and nuclear medicine tracers can facilitate early diagnosis and evaluation of therapy response. Furthermore, molecular radionuclide therapy –using radionuclides with therapeutic instead of diagnostic properties– also allows for targeted treatment. The group focuses on investigations of biodistribution, dosimetry and treatment planning for existing and novel radionuclide therapies, in order to improve the treatment regimens or introduce new radiopharmaceuticals in the clinic. Furthermore, the research group is performing quantitative PET and SPECT imaging studies, pharmacokinetic modelling and advanced image analyses in various clinical trials.